Table 2.
Summary of the current literature on the role of pannexin channels in different cancer types
| Pannexin | Cancer type | Description | Reference |
|---|---|---|---|
| Panx1 | Breast | Gain of function mutation in PANX1 increases metastasis | [162] |
| Panx1 | Melanoma | Upregulated expression. Knockdown induces re-differentiation | [33, 154] |
| Panx1 | Glioma | Tumour suppressor when overexpressed in Panx1-deficient rat C6 glioma cells, but endogenously expressed in human glioma cell lines. Accelerates glioma tumor aggregate formation |
[153, 181] |
| Panx1 | Glioma | Panx1 siRNA reduces proliferation of U87-MG human glioma cells | [155] |
| Panx1 | Hepatocellular carcinoma | Upregulation linked to cancer spread in aggressive Hca-F cell lines | [157] |
| Panx1 | Multiple myeloma | Gene amplification and upregulation in myeloma cell lines | [158] |
| Panx1 | Colon | Interaction with Liver X receptor β for pyroptotic cell death | [178] |
| Panx1 | Leukemia Osteosarcoma |
Upregulated in leukemic cells compare to T-cells. Activated by chemotherapy drugs and immunogenic therapy to release ATP |
[156, 186] |
| Panx1 | Prostate | Bystander cell killing effect of TMPK/AZT | [185] |
| Panx1 | Gall bladder adenocarcinoma | Downregulated expression in tumours | [3] |
| Panx2 | Glioma | Tumour suppressor overexpressed in C6 glioma cells. Downregulated in human tumours and positive correlation with patient survival | [179, 183] |
| Panx2 | Hepatocellular carcinoma | Potential tumour suppressor. Methylated in cancer samples | [184] |
| Panx2 | Neuroblastoma | Knockdown in Neuro2a cells increases differentiation | [21] |
| Panx1, Panx3 | Basal and squamous skin cell carcinoma | Downregulated in BCC and SCC tumours compared to normal skin | [152] |